New IGF-1R antibody Lumvoa receives FDA nod for active and chronic thyroid eye disease, offering rapid proptosis relief and diplopia improvement. Viridian Therapeutics has received FDA approval for ...
The investigators use mindfulness-based cognitive therapy (MBCT) on patients who have never previously practiced the technique, with the aim of possibly re-training their brains to remove their static ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19 ...
Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment. The US Food and Drug Administration (FDA) recently agreed to the expansion of ...
The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.
Explore early MacTel diagnosis with OCT/FA, who qualifies for Encelto implant, and how costs, reimbursement, and surgery shape timely retina care. Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina ...
A modular AI system comprising six transformer models achieves near-expert concordance with an ASUWOG-aligned composite inflammation score Uveitis is the third leading cause of blindness in ...
Carl D. Regillo, MD, FACS, reviews long-term efficacy and safety findings from the Port Delivery System clinical trial program. Seven years of follow-up data from the Port Delivery System (PDS) ...
SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care. Barakat opened by highlighting what makes CTS uniquely valuable ...
The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...
This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results